AIGIV
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anthrax
Conditions
Anthrax
Trial Timeline
Nov 30, 2026 → Aug 1, 2027
NCT ID
NCT03569514About AIGIV
AIGIV is a pre-clinical stage product being developed by Emergent BioSolutions for Anthrax. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03569514. Target conditions include Anthrax.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03569553 | Pre-clinical | Recruiting |
| NCT03569514 | Pre-clinical | Recruiting |
Competing Products
15 competing products in Anthrax